Mixed news for Lilly drug pipeline-WEB ONLY
Eli Lilly and Co. got good news and bad news Friday. The same day U.S. regulators recommended Lilly’s blood thinner prasugrel for market approval, one of the Indianapolis pharmaceutical company’s partners reported poor clinical results for one of its most promising drugs. Canada-based BioMS Medical Corp. said its lead drug for treating relapse remitting multiple […]